Within our Pharmaceutical Development & Manufacturing framework, we focus specifically on Biosimilar Development for Fc fusion proteins. We deliver phase-appropriate, laboratory-centric CDMO services to de-risk development and establish robust, manufacturable drug workflows tailored to Fc fusion modalities.
Overview of Fc Fusion Protein Biosimilar
Fc fusion proteins (FcFPs) are engineered biologics formed by fusing an active protein domain—such as a receptor ectodomain, ligand-binding motif, enzyme fragment, cytokine variant, or bioactive peptide—to the Fc region of immunoglobulin G. The Fc domain supports extended persistence via FcRn engagement, improves biophysical stability, and enables scalable purification through Protein A or Fc-specific platforms. As multi-domain glycoproteins, FcFPs exhibit inherent heterogeneity—glycosylation profiles, C-terminal variants, oxidation/deamidation liabilities, and higher-order structure—requiring advanced analytics and carefully tuned upstream and downstream parameters. For biosimilars, the central objective is analytical similarity to a reference standard across critical quality attributes (CQAs) while converging on manufacturability, stability, and consistent lot-to-lot performance suited to large-scale, compliant production.
Our Services
We provide an integrated set of development services for FcFP biosimilars. The program spans analytical similarity, cell line and upstream optimization, downstream purification and polishing, formulation and stability engineering, all aligned to biosimilar CQA targets.
Analytical Similarity & CQA Definition Service
We establish a risk-ranked target product profile specific to FcFPs and define CQAs through orthogonal characterization. Workflows include intact and subunit mass spectrometry, peptide mapping, glycan profiling (2-AB/2-AA labeling and LC-FLD/MS), charge variant analysis (icIEF/CEX), disulfide mapping, free thiol and oxidation monitoring, DSC/DLS for higher-order structure, and host-cell impurity tracing. Similarity ranges are statistically justified and linked to control strategies.
Cell Line & Upstream Process Development Service
Using industry-standard CHO systems, we select clones for sequence fidelity, stable productivity, and quality attributes aligned to the biosimilar target (e.g., Fc glycan distribution, clipping minimization). We optimize media and feed strategies to control growth, lactate/ammonia trajectories, and glycosylation, balancing titer with CQA stewardship.
Downstream Purification & Polishing Service
We design Fc-aware purification trains: Protein A (or Fc-capture alternatives), low-pH viral inactivation hold compatibility, intermediate ion-exchange polishing to tune charge variants, and HIC/SEC steps to manage aggregates and fragments. Resin screening, load/wash/elute design spaces, and resin lifetime studies converge on high-yield recovery with tight impurity clearances. Hold-time and pool-compatibility studies protect Fc integrity.
Formulation & Stability Engineering Service
We develop buffer systems that preserve multi-domain conformation and minimize interface-induced stress. Accelerated and stress stability studies (thermal, agitation, freeze–thaw, photo) inform excipient selection, pH/ionic strength windows, and container–closure compatibility. Aggregation kinetics, opalescence, subvisible particles, and methionine/tryptophan oxidation are monitored to refine the protective formulation envelope.
Potency & Functional Bioassay Development Service
We establish mechanism-relevant bioassays for biosimilarity decisions, including ligand-binding ELISAs/surface plasmon resonance, receptor competition assays, and cell-based signal-transduction readouts. Where Fc effector function is non-primary, we qualify orthogonal assays (FcRn binding, FcγR panel binding) to document functional parity without emphasizing cytotoxic mechanisms.
Charge Variant & Glycosylation Control Strategy Service
We link process parameters to charge and glycan CQAs through DoE. For FcFPs, sialylation, galactosylation, and fucosylation can influence solubility and Fc interactions; we engineer upstream levers and polishing conditions to keep variants within similarity corridors.
Our FcFP Biosimilar Portfolio
We support development for mainstream Fc fusion formats. The following categories illustrate common, representative classes that we provide:
- Receptor ectodomain–Fc fusions (e.g., TNF receptor family, IL receptor fragments)
- Ligand trap–Fc fusions (e.g., VEGF-binding constructs, chemokine traps)
- Immune checkpoint–related domain–Fc fusions (e.g., CTLA-4 extracellular domain–Fc)
- Enzyme or enzyme fragment–Fc fusions
- Cytokine variant–Fc fusions
- Peptide/peptidomimetic–Fc fusions ("Peptibodies")
We deliver a tightly integrated, biosimilar-focused CDMO program for FcFPs—from analytical similarity and process definition to formulation and bioassay strategy. Engage our team to accelerate development while protecting biosimilar CQAs and manufacturability.
Our products and services are for research use only.
